Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inovio Pharmaceuticals has signed an agreement with OncoSec Medical, providing for the sale to OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.
Subscribe to our email newsletter
OncoSec will pay Inovio an undisclosed purchase price for the assigned assets and cash fees and a royalty on commercial product sales.
The electroporation technology being sold and licensed to OncoSec is based on Inovio’s electroporation technology platform that, in addition to DNA vaccines and immune therapeutics, can also be used to efficiently deliver a chemotherapeutic or cytokine agent for the treatment of cancer.
The therapies enable heightened concentrations of medicine to be directed to the cancer while reducing overall dosage and moderating or eliminating side effects associated with systemically-applied therapeutic approaches.
The optimized delivery is enabled by Inovio’s proprietary electroporation process, which locally applies brief controlled electrical pulses to cells to temporarily and reversibly increase permeability of the cell membranes in selected tissue and increase cellular uptake of the previously injected agent as seen in previous animal studies and earlier human clinical trials.